UA97960C2 - USE OF ESTRADIOL VALERATE OR 17b-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO - Google Patents

USE OF ESTRADIOL VALERATE OR 17b-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO

Info

Publication number
UA97960C2
UA97960C2 UAA200904273A UAA200904273A UA97960C2 UA 97960 C2 UA97960 C2 UA 97960C2 UA A200904273 A UAA200904273 A UA A200904273A UA A200904273 A UAA200904273 A UA A200904273A UA 97960 C2 UA97960 C2 UA 97960C2
Authority
UA
Ukraine
Prior art keywords
estradiol
combination
dienogest
maintaining
increasing
Prior art date
Application number
UAA200904273A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Сузан Цойн
Хольгер Циммерманн
Сузанне Парке
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Priority claimed from PCT/EP2007/008866 external-priority patent/WO2008046559A1/en
Publication of UA97960C2 publication Critical patent/UA97960C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of estradiol valerate or estradiol in combination with 17α-cyanomethyl-17-β-hydroxyestra-4,9-dien-3-one (dienogest) in a multiphase or single-phase combination preparation for oral therapy for maintaining and/or increasing the female libido, optionally also in unity with oral contraception. The total daily dose units of the multiphase combination and of the pharmaceutically acceptable placebo or of the single-phase combination and the active-ingredient-free and placebo-free daily dose units correspond to 28 days.
UAA200904273A 2006-10-20 2007-10-12 USE OF ESTRADIOL VALERATE OR 17b-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO UA97960C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06022091 2006-10-20
PCT/EP2007/008866 WO2008046559A1 (en) 2006-10-20 2007-10-12 USE OF ESTRADIOL VALERATE OR 17β-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO

Publications (1)

Publication Number Publication Date
UA97960C2 true UA97960C2 (en) 2012-04-10

Family

ID=37491810

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200904273A UA97960C2 (en) 2006-10-20 2007-10-12 USE OF ESTRADIOL VALERATE OR 17b-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO

Country Status (3)

Country Link
CN (1) CN101553234A (en)
SG (1) SG175658A1 (en)
UA (1) UA97960C2 (en)

Also Published As

Publication number Publication date
CN101553234A (en) 2009-10-07
SG175658A1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
MX2009004179A (en) Use of estradiol valerate or 17î²-estradiol in combination with dienogest for oral therapy for maintaining and/or increasing the female libido.
MXPA06013133A (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction.
RS20060348A (en) Extended use combination comprising estrogens and progestins
MX2008011978A (en) Treatment of triple receptor negative breast cancer.
RU2009148278A (en) The use of estriol in a low dose
MX2009004616A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens.
NZ602698A (en) Parenteral pharmaceutical form which releases aromatase inhibitor and gestagens, for the treatment of endometriosis
HUP0402142A2 (en) Composition of estrogen/gestagen combination, preparation and application thereof
UA94909C2 (en) Pharmaceutical composition of a neuroactive steroid and use thereof
TW200603787A (en) Topical preparations containing ambroxol
IL197574A0 (en) Pharmaceutical compositions
MX2010004353A (en) Antiemetic-oral contraceptive combination.
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
TW200514560A (en) Pharmaceutical formulation for contraception and hormone-replacement therapy
PL382307A1 (en) The manner of preparation of pharmaceutical composition in form of quick dispersive dose and stable, oral, quickly dispersive form of a dosage
AR049196A1 (en) HORMONAL CONTRACEPTIVE CONTAINING A COMBINATION OF ETHYLINESTRADIOL AND CLORMADINONE ACETATE
AR065816A1 (en) ORAL CONTRACEPTIVE REGIME
YU66202A (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin
TW200638951A (en) Solid oral pharmaceutical form for contraception
UA97960C2 (en) USE OF ESTRADIOL VALERATE OR 17b-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
MX2009008813A (en) Pharmaceutical composition containing phloroglucinol and paracetamol.
EA200701389A1 (en) SOLID ORAL MEDICAL FORM FOR CONTRACEPTION
TN2009000263A1 (en) Pharmaceutical preparation for the alleviation of endometriosis
TW200640468A (en) Pharmaceutical product for oral contraception